Pharmacogenomics of neurodegenerative diseases

European Journal of Pharmacology

Volumn 413, Issue 1, 2001, Pages 11-29

  Maimone, Davide ^a   Dominici, Roberto ^b   Grimaldi, Luigi M E ^b,c,d  

^a GARIBALDI HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c AUSL 2   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer disease; Amyotrophic lateral sclerosis; Gene mutation; Gene polymorphism; Parkinson disease; Pharmacogenomics

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; PARKINSON DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0035830630     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00939-0     Document Type: Review

References (186)

1. A wide range of mutations in the parkin gene is responsible for autosomal recessive parkinsonism in Europe
2. Immunochemical identification of the serine protease inhibitor, α-1-antichymotripsin in the brain amyloid deposits
3. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease
4. β-Amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NFkB-inducing kinase-dependent signaling mechanism
5. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis
6. 2+-binding proteins in selective motor neuron vulnerability in amyotrophic lateral sclerosis
7. Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis
8. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis
9. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex
10. Excitatory aminoacid transporter 5, a retinal glutamate transporter coupled to a chloride conductance
11. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease
12. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
13. A controlled trial of riluzole in amyotrophic lateral sclerosis
14. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
15. Alpha-2-macroglobulin is genetically associated with Alzheimer's disease
16. Glutamate and Parkinson's disease
17. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis
18. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity
19. Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease
20. Alzheimer's disease in the National Academy of Sciences-National Research council Registry of Agin Twin Veterans: III. Detection of cases, longitudianl results, and observations on twin concordance
21. Amyotrophic lateral sclerosis. Insights from genetics
22. Failure of immunosuppression with a 10- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis
23. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
24. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice
25. 2+ rises and consequent oxygen radical production
26. APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease
27. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms
28. A genetic polymorphism of monoamino oxidase-B modifies the association of cigarette smoking and Parkinson's disease
29. Experimental destruction of substantia nigra initiated by Parkinson's disease immunoglobulins
30. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: A meta-analysis
31. Synucleins in synaptic plasticity and neurodegenerative disorders
32. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early onset Parkinson's disease
33. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease
34. Progressive neuropathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis
35. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite
36. Distribution of AMPA-selective glutamate receptor subunits in the human hippocampus and cerebellum
37. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
38. Cortical biopsy in Alzheimer's Disease: Diagnostic accuracy and neurochemical, neuropathological and cognitive correlations
39. Protective and rescuing abilities of IGF-I and some putative free radical scavengers against β-amyloid-inducing toxicity in neurons
40. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation
41. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease
42. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
43. +: Implications for neurodegeneration
44. Familial aggregation of Parkinson's disease. A population-based case-control study in Europe
45. Prospects for pharmacological intervention in Alzheimer's disease
46. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis
47. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis
48. 2+ and induce ultrastructural changes in motor neurons
49. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1
50. An excitatory amino acid transporter with properties of a ligand-gated chloride channel
51. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies
52. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis
53. Neuropathology of Parkinson's disease
54. Neurotransmitters and neuropeptides
55. Abnormalities in neural circuitry in Alzheimer's disease: The hippocampus and cortical cholinergic innervation
56. Potential implications of a CNTF gene mutation in a German population for patients with motor neuron disease
57. Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis
58. α-Synuclein and the Lewy body
59. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism
60. Activation of caspase-3 in β-amyloid-induced apoptosis of cultured rat cortical neurons
61. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
62. The very low density lipoprotein (VLDL) receptor is a genetic susceptibility factor for Alzheimer disease in a European Caucasian population
63. Cytopathology of amyotrophic lateral sclerosis
64. Glial cells and Parkinson's disease
65. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
66. Alterations in neurotrophins and neurotrophin receptors in Alzheimer's disease
67. Biochemical pathophysiology of Parkinson's disease
68. 2+ evoked by NMDA and veratridine in rat cultured granule cells: Evidence for a dual mechanism of action
69. Interleukin-6 is present in early stages of plaque formation and is restricted to the brain of Alzheimer's disease patients
70. Nuclear translocation of NF-kB is increased in dopaminergic neurons of patients with parkinson disease
71. The role of the low density lipoprotein receptor related protein (LPR) in Aβ metabolism and Alzheimer's disease
72. Polymorphisms in the glutamate transporter gene EAAT2 in European amyotrophic lateral sclerosis patients
73. Therapeutic strategies in Parkinson's disease
74. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism
75. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease
76. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
77. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism
78. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
79. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype
80. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
81. Effect of recombinant insulin-like growth factor-1 on progression of amyotrophic lateral sclerosis. A placebo controlled study
82. MTPT: The promise of a new neurotoxin
83. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease
84. A clinical genetic study of Parkinson's disease: Evidence for dominant transmission
85. Excitotoxicity in amyotrophic lateral sclerosis
86. The ubiquitin pathway in Parkinson's disease
87. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
88. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease
89. Functional role of caspase-1 and caspase-3 in an amyotrophic lateral sclerosis transgenic mouse model
90. Apolipoprotein E and alpha-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease
91. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain?
92. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk
93. Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's disease
94. Aberrant RNA processing in a neurodegenerative disease: A common cause for loss of glutamate transport EAAT2 protein in sporadic amyotrophic lateral sclerosis
95. 2+ in homeostasis
96. Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
97. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis
98. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
99. The topography of cell loss from locus coeruleus in Alzheimer's disease
100. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality
101. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: Studies on Parkinson's and incidental Lewy body disease
102. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
103. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1
104. Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1
105. Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders
106. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis
107. Variations in the monoamine oxidase B (monoamino oxidase B) gene are associated with Parkinson's disease
108. Parkinson's disease, pesticides, and glutathione transferase polymorphisms
109. Histochemical detection of apoptosis in Parkinson's disease
110. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease
111. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
112. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis
113. Immunocytochemical and ultrastructural study of Lewy-body-like inclusions in familial amyotropic lateral sclerosis
114. Recent advances in the neurochemical pathology of Alzheimer's disease. Studies of neuropeptides, cholinergic function and Alzheimer's disease-associated protein
115. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
116. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced
117. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease
118. Iron and neurodegeneration: Prospects for neuroprotection
119. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in Parkinson's disease
120. Amyotrophic lateral sclerosis serum factors enhance spontaneous and evoked transmitter release at the neuromuscular junction
121. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease
122. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease
123. Amyloid β peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons
124. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for Parkinson's disease
125. Increased risk of Parkinson's disease in parents and siblings of patients
126. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins
127. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: Evidence for association of a DRD2 allele
128. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
129. Protective effect of transforming growth factor-β 1 on β-amyloid neurotoxicity in rat hippocampal neurons
130. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease
131. Mechanism of MTPT toxicity
132. 2+ superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury
133. Mitochondrial dysfunction. A pathogenic factor in Parkinson's disease
134. APOE genotyping and response to drug treatment in Alzheimer's disease
135. P450 enzymes and Parkinson's disease: The story so far
136. Genetic influence on the development of Parkinson's disease
137. Neuroprotection by the inhibition of apoptosis
138. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences
139. The molecular and genetic basis of Alzheimer disease: The end of the beginning
140. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity
141. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis
142. CYP2D6 polymorphism and Parkinson's disease susceptibility
143. Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease
144. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the Parkinson's disease amyloid precursor protein mouse
145. Nerve growth factor and Alzheimer's disease
146. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease
147. Translating cell biology into therapeutic advances in Alzheimer's disease
148. Cryptic physiological trophic support of motor neurons by Lif revealed by double gene targeting of CNTF and Lif
149. Evidence for mitochondrial dysfunction in Parkinson's disease: A critical appraisal
150. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: Implication for neuritic plaque formation in Alzheimer's disease
151. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
152. 2+ in motor nerve terminals in amyotrophic lateral sclerosis
153. Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease
154. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
155. Environmental agents and Parkinson's disease
156. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death
157. The risk of Alzheimer's disease and duration of NSAID use
158. Molecular genetics of Alzheimer's disease
159. Origin and functional consequences of the complex I defect in Parkinson's disease
160. Matrilinear inheritance of complex I dysfunction in a multigenerational Parkinson's disease family
161. 2+ influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis
162. Variability and validity of polymorphism association studies in Parkinson's disease
163. Effect of oestrogen during menopause on risk and age-at-onset of Alzheimer's disease
164. Peroxynitrite inhibits glutamate transporter subtypes
165. Caspase-2 mediates neuronal cell death induced by β-amyloid
166. Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins
167. Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample
168. Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis
169. Polymorphism in the parkin gene in sporadic Parkinson's disease
170. Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease
171. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB
172. Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches
173. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
174. 2+-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: A molecular determinant of selective vulnerability in amytrophic lateral sclerosis
175. Neurochemistry and neuropharmacology of Parkinson's disease
176. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease
177. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease
178. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease
179. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides
180. Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons
181. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-β peptide degradation
182. Mechanisms of neuronal degeneration in Alzheimer's disease
183. Case-control study of presenilin-1 intronic polymorphism in sporadic early and late onset Alzheimer's disease
184. Amyloid β and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia
185. Apoptosis related antigen, Le(y) and nick-end labelling are positive in spinal motor neurons in amyotrophic lateral sclerosis
186. Therapeutic potential of neurotrophic factors for neurological disorders